For companies working on cell and gene therapies, preparing the reagents required for product development and scale-up can take lots of time and money. Stephen Gunstream, CEO, and his team at Teknova hope to change that. “We provide customers with the right reagents they need for their applications, and we allow easy scale up from R&D to commercial production,” he says.
In bioprocessing for monoclonal antibodies over the past 30 years, many advances in standardizing the production process has made it easier to scale. With the advent of personalized medicine, cell and gene therapies are now in a transformational phase, moving from exploratory technologies to mainstream therapy.